ArticleMedical care2011
Tradeoffs of using administrative claims and medical records to identify the use of personalized medicine for patients with breast cancer.
Article in Medical care, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Sensitivity and specificity of International Classification of Diseases algorithms (ICD-9 and ICD-10) used to identify opioid-related overdose cases: A systematic review and an example of estimation using Bayesian latent class models in the absence of gold standards.Canadian journal of public health = Revue canadienne de sante publique · 2024Pooled it
- Validity of International Classification of Diseases codes in identifying illicit drug use target conditions using medical record data as a reference standard: A systematic review.Drug and alcohol dependence · 2020Pooled it
- Measuring the Direct Medical Costs of Hospital-Onset Infections Using an Analogy Costing Framework.PharmacoEconomics · 2024Article
- An analytical framework for breast cancer public policies in Sub-Saharan Africa: results from a comprehensive literature review and an adapted policy Delphi.BMC public health · 2024Review
- Exploration of PCORnet Data Resources for Assessing Use of Molecular-Guided Cancer Treatment.JCO clinical cancer informatics · 2020Article
- Clinical Molecular Marker Testing Data Capture to Promote Precision Medicine Research Within the Cancer Research Network.JCO clinical cancer informatics · 2019Article
- Validity of Administrative Databases in Comparison to Medical Charts for Breast Cancer Treatment Data.Journal of cancer epidemiology · 2018Article
- A feasibility study to assess the validity of administrative data sources and self-reported information of breast cancer survivors.Israel journal of health policy research · 2016Observational
- First do no harm: population-based study shows non-evidence-based trastuzumab prescription may harm elderly women with breast cancer.Breast cancer research and treatment · 2014Article
- Intended versus inferred care after PET performed for initial staging in the National Oncologic PET Registry.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2013Article
- Identifying specific chemotherapeutic agents in Medicare data: a validation study.Medical care · 2013Article
- Intended versus inferred management after PET for cancer restaging: analysis of Medicare claims linked to a coverage with evidence development registry.Medical care · 2013Article
- Gene expression profile testing for breast cancer and the use of chemotherapy, serious adverse effects, and costs of care.Breast cancer research and treatment · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundAdministrative claims and medical records are important data sources to examine healthcare utilization and outcomes. Little is known about identifying personalized medicine technologies in these sources.
objectivesTo describe agreement, sensitivity, and specificity of administrative claims compared with medical records for 2 pairs of targeted tests and treatments for breast cancer. RESEARCH
designRetrospective analysis of medical records linked to administrative claims from a large health plan. We examined whether agreement varied by factors that facilitate tracking in claims (coding and cost) and that enhance medical record completeness (records from multiple providers). SUBJECTS: Women (35 to 65 y of age) with incident breast cancer diagnosed in 2006 to 2007 (n=775). MEASURES: Use of human epidermal growth factor receptor 2 (HER2) and gene expression profiling (GEP) testing, trastuzumab, and adjuvant chemotherapy in claims and medical records.
resultsAgreement between claims and records was substantial for GEP, trastuzumab, and chemotherapy, and lowest for HER2 tests. GEP, an expensive test with unique billing codes, had higher agreement (91.6% vs. 75.2%), sensitivity (94.9% vs. 76.7%), and specificity (90.1% vs. 29.2%) than HER2, a test without unique billing codes. Trastuzumab, a treatment with unique billing codes, had slightly higher agreement (95.1% vs. 90%) and sensitivity (98.1% vs. 87.9%) than adjuvant chemotherapy.
conclusionsHigher agreement and specificity were associated with services that had unique billing codes and high cost. Administrative claims may be sufficient for examining services with unique billing codes. Medical records provide better data for identifying tests lacking specific codes and for research requiring detailed clinical information.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.